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Summary 
A novel tumor necrosis factor (TNF) family member 
has been cloned and characterized. This protein, des- 
ignated TNF-related apoptosis-Inducing ligand (TRAIL), 
consists of 291 and 291 aa in the human and murine 
forms, respectively, which share 65% aa identity. 
TRAIL is a type II membrane protein, whose C-terminal 
extracellular domain shows clear homology to other 
TNF family members. TRAIL transcripts are detected 
in a variety of human tissues, most predominantly in 
spleen, lung, and prostate. The TRAIL gene is located 
on chromosome 3 at position 3926, which is not close 
to any other known TNF llgand family members. Both 
full-length cell surface expressed TRAIL and picomo- 
lar concentrations of soluble TRAIL rapidly induce 
apoptosis in a wide variety of transformed cell lines 
of diverse origin. 
Introduction, 
Tumor necrosis factor (TNF) is the prototypic member of 
an emerging family of cytokines that function as prominent 
mediators of immune regulation and the inflammatory re- 
sponse.The apparent involvement of TNF in septic shock, 
autoimmune disorders, and graft-versus-host disease is 
well documented (reviewed by Revel and Schattner, 1987; 
Cerami and Beutler, 1988; Cohen, 1988). Eight other 
members of this family are currently known, including 
lymphotoxin (LTa, TNFf3), lymphotoxin 8 (LTP), and li- 
gands for CD40, CD30, CD27, 0X40, 4-lBB, and Fas 
(APO-l) (Cosman, 1994). With one exception, all ligands 
are type II membrane proteins, with homology confined 
to the C-terminal - 150 residues. The exception, LTa, ap- 
pears to be a secreted protein that can also be found cell 
surface-associated via its interaction with another TNF 
family member, LTp (Browning et al., 1993). In addition, 
a proteolytically processed soluble form of TNF has long 
been recognized (Pennica et al., 1984). These ligands in- 
teract with a parallel family of some twelve homologous 
receptors, characterized by cysteine-rich pseudorepeats 
in the extracellular region, which as with the ligands, are 
variably expressed on a variety of cell types, including B 
cells, T cells, dendritic cells and macrophage (Smith et 
al., 1994). 
Direct evidence for crucial roles of many of these family 
members comes from aberrant phenotypes arising from 
spontaneous mutations or targeted gene inactivation in 
mice. Loss of function mutations in either the murine Fas 
ligand (g/d), murine Fas receptor (Ipr), or human Fas recep- 
tor results in lymphadenopathy and autoimmune disorders 
(Watanabe-Fukunaga et al., 1992; Adachi et al., 1993; Ta- 
kahashi et al., 1994; Fisher et al., 1995; Rieux-Laucat et 
al., 1995). One implication is the involvement of Fas in 
the establishment of peripheral tolerance. Similarly, muta- 
tions in human CD40 ligand give rise to hyper-immuno- 
globulin M (IgM) phenotypes in patients, consistent with 
in vitro evidence suggesting an essential role in B cell 
affinity maturation and immunoglobulin isotype switching 
(Allen et al., 1993). Targeted inactivation mutants for mu- 
rine TNFR type I(p55) are vastly more susceptible to cer- 
tain microbial infections, such as Listeria monocytogenes, 
consistent with a protective effect for TNF (Pfeffer et al., 
1993; Rothe et al., 1993). Finally, disruption of the murine 
LTa gene results in complete loss of peripheral lymph 
nodes (De Togni et al., 1994). 
A unique feature of this family of ligands is the ability 
of some members to induce directly the apoptotic death 
of chronically activated T cells and B cells (Daniel and 
Krammer, 1994; Alderson et al., 1995). Likewise, TNF has 
been shown to induce apoptosis in normal thymocytes 
under appropriate conditions (Hernandez-Caselles and 
Stutman, 1993). Further, peripheral T cells from HIV- 
infected individuals have been shown to be much more 
sensitive to Fas-mediated apoptosis than uninfected con- 
trols (Katsikis et al., 1995). 
Because of their fundamental roles in immune and de- 
velopmental networks, and particularly the involvement in 
programmed cell death, we have searched the expressed 
sequence tag (EST) library using homology to a consensus 
amino acid sequence based upon the portion of the 
P-pleated sheet that is most conserved across known TNF 
ligand family members (see Discussion). This screen iden- 
tified an EST potentially encoding a new member of this 
family. Full-length human and murine cDNAs were subse- 
quently cloned and sequenced, and the sequence con- 
firmed an open reading frame predicted to encode a type 
II membrane protein with significant homology to the TNF 
ligand family. Biological studies using either the cell-bound 
ligand or an engineered soluble form demonstrated its 
ability to induce apoptosis in a wide variety of transformed 
cell lines. 
Results 
Isolation of Human and Murine CONAS 
Encoding TRAIL 
A BLAST search of the National Center for Biotechnology 
Information dbEST data base using a consensus amino 
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acid sequence based upon the most conserved region of 
the TNF family (see Discussion and Experimental Proce- 
dures), returned an EST derived from a human heart 
atrium cDNA library, which appeared to be a potential new 
member of the TNF ligand family. To obtain full-length 
cDNA, a human peripheral blood lymphocyte (PBL) and 
human heartcDNAlibraries(StratageneCloningSystems, 
La Jolla, California) were screened using oligonucleotide 
probes based on the sequence of the EST. Several clones 
were sequenced and aligned. The resulting consensus 
sequence of the TRAIL cDNA (1769 bp; Figure l), contains 
an open reading frame capable of encoding a protein of 
261 aa. In addition, 24 bp upstream of the 3’poly(A) stretch 
is a consensus hexanucleotide polyadenylation signal, 
5’-AAUAAA-3’. Furthermore, there is an in-frame stop co- 
don upstream of the predicted initiation codon, indicating 
that translation cannot initiate upstream of the putative 
start codon. Each base of the predicted coding region was 
covered by at least two separately obtained clones. 
Several homologous murine TRAIL cDNAs were iso- 
lated from a cDNA library prepared from the murine helper 
T cell line, 789, by cross-hybridization using as a probe 
the coding region of human TRAIL, which had been radio- 
labeled by random priming. The murine TRAIL-predicted 
coding region is 291 aa in length and 65% identical to the 
human homolog. 
Hydrophilic@ analysis of the human and murine TRAIL 
protein products predicts a single internal hydrophobic do- 
main and the absence of a signal sequence. This structure 
is characteristic of a type II membrane protein with the 
C-terminal region extracellular. Consistent with this is 
the presence of potential N-linked glycosylation sites in 
the C-terminal domains, at amino acids 109 and 52 of the 
human and murine proteins, respectively. However, the 
site on the human protein may not be efficiently glycosy- 
lated due to the presence of an adjacent proline (Gavel 
and von Heijne, 1990). 
Northern Analysis of Human and Murine TRAIL 
Figure 2 shows Northern blot analysis of the expression 
of human TRAIL transcripts in various tissues and cells. 
The predominant RNA band in the blots has a size of 
1.6-2.0 kb. TRAIL transcripts were seen in many human 
tissues, particularly in spleen, prostate, and lung. No tran- 
scripts were detected in brain, liver, or testis. TRAIL tran- 
scripts were also abundant in the large cell anaplastic lym- 
phoma cell line K299, and in tonsilar T cells, but were 
present to a lesser degree in the Burkitt lymphoma line 
Raji. Northern blot analysis of several T cell lines failed 
to detect any TRAIL transcripts (data not shown). Further- 
more, little or no expression of TRAIL transcripts were 
detected in freshly isolated PBT cells, both unstimulated 
or stimulated with PMA and calcium ionophore for 20 hr 
(data not shown). 
DNA Fragmentation induced by TRAIL 
We have found that TRAIL, expressed on the surface of 
transfected cells as well as a soluble form discussed in 
the next section, induces apoptosis in avarietyof cell lines. 
Fixed CVllEBNA cells transfected with a vector express- 
ing the full-length surface-bound form of TRAIL (pDC409- 
TRAIL) were examined for their ability to induce apoptotic 
death in target cells utilizing a DNA fragmentation assay 
that was performed after a 4 hr coculture of these fixed 
cells with either Jurkat or U937 cells (1:4 ratio of effector 
to target cells). As a positive control, we used soluble re- 
combinant Fas ligand, which is known to induce apoptosis 
in Jurkat cells. Fragmented DNA in the cellular cytoplasm 
was recovered and resolved by agarose gel electrophore- 
sis. The results demonstrate that, like conditioned super- 
natant from cells expressing Fas ligand, fixed cells ex- 
pressing TRAIL induce DNA laddering in both Jurkat and 
U937 cells (Figure 3). This fragmentation of cellular DNA 
into soluble multimers of - 160 bp is a hallmark of 
apoptosis. The monoclonal antibody to human Fas (M3) 
has previously been shown to block activity of Fas ligand 
(Ramsdell et al., 1994). Consistent with this result, DNA 
laddering induced by Fas ligand is significantly reduced 
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by pretreatment of the Jurkat cells with M3. The apoptotic 
death of the Jurkat cells induced by TRAIL was not af- 
fected by pretreatment with M3, indicating that TRAIL- 
induced apoptosis is not mediated through Fas. 
Characterization of Soluble TRAIL 
To facilitate biological studies, we constructed an epitope- 
tagged soluble form of TRAIL. Based upon published re- 
ports that state that the C-terminal conserved extracellular 
region of TNF is sufficient for biological activity, and that 
deletions of N-terminal residues can increase activity 
(Creasey et al., 1987), it seemed probable that the homo- 
logous C-terminal domain of TRAIL would be sufficient 
to produce biologically active protein. Soluble TRAIL- 
expressing expressing vector was made by fusing in- 
frame DNA encoding the following amino acid sequences 
(listed from 5’to 3, respectively): a leader sequence from 
human cytomegalovirus (CMV), a synthetic antibody epi- 
tope (Flag), and amino acids 95-281 of human TRAIL. As 
shown in Figure 4, the soluble recombinant TRAIL ex- 
pressed in CVllEBNA cells has an apparent molecular 
weight of 28 kDa by SDS-PAGE. Gel filtration analysis of 
the purified soluble TRAIL suggests that the native mole- 
cule is multimeric in solution with a size of - 80 kDa (data 
not shown). A similar soluble form of murine TRAIL has 
also been expressed (data not shown). 
Biological Activity of Soluble TRAIL 
To investigate the activity of soluble TRAIL, Jurkat cells 
were treated with either conditioned supernatant from 
cells transfected with the solubte TRAIL construct, Fas 
Figure 2. Northern Blot Analysis of TRAIL 
Transcripts 
RNAs isolated from the indicated tissues were 
resolved on a formaldehyde-agarose gel, blot- 
ted onto a positively charged nylon membrane, 
and probed with labeled antisense TRAIL- 
encoding RNA. Positions of RNA size markers 
in kb are shown on the left. Shown are blots 
using RNA from whole tissues (A,B) or cell lines 
and purified cells (C). All lanes used 2 ug 
poly(A)+ RNA, except for the K299 lane, which 
used 5 pg of total RNA. 
Lane Ml23456789 
Fixed CVUEBNA ---+- 
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Figure 3. Apoptotic DNA Laddering Induced by TRAIL 
Jurkat or U937 cells were cultured for 4 hr with fixed cells or soluble 
factors as indicated, then fragmented DNA in thecytoplasm was recov- 
ered and resolved by 1.5% agarose gel electrophoresis. Fixed cells 
were obtained by transfecting CVllEBNA cells with vector alone or 
TRAIL expressing vector, and treating the cells with 1% paraformalde- 
hyde in PBS. Fas ligand was obtained from supernatants of transiently 
expressing COS cells. Blocking a-Fas antibody used is a monoclonal 
antibody, M3. The size marker in lane M is (~~174 DNA digested with 
Haelll. 
ligand, or empty vector. The viability of target cells after 
incubation with 10 &I of conditioned supernatants for 20 hr 
was monitored by metabolic conversion of the dye alamar 
blue. The results, shown in Figure 5A, demonstrate that 
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Figure 4. Coomassie Stained SDS-PAGE of Purified Soluble TRAIL 
Supernatants from CVllEBNA cells transfected with pDC409-Flag- 
TRAIL were applied to an a-Flag antibody column. Soluble TRAIL 
protein was eluted with citrate, neutralized with Tris, and resolved 
by SDS-PAGE. Sizes in kilodaltons of molecular mass markers are 
indicated on the left. 
while both Fas ligand and TRAIL kill Jurkat cells, only 
killing by Fas ligand can be inhibited by addition of blocking 
antibody to Fas. Furthermore, killing by soluble TRAIL, 
which has been constructed with an artificial Flag epitope, 
can be enhanced by immobilizing anti-Flag antibody to 
the plate prior to adding TRAIL conditioned supernatant. 
This presumably facilitates cross-linking of the ligand- 
receptor complexes, thereby increasing the strength of 
signaling. 
Since the process of apoptosis rapidly induces dramatic 
effects on cellular structure, the effects of TRAIL on Jurkat 
cells were visualized by confocal microscopy. Jurkat cells 
were treated with purified TRAIL or with an agonist anti- 
body to human Fas receptor (CHll) for 2.5 hr (Yonehara 
et al., 1989). The cells were stained with fluorescence- 
conjugated reporter dyes, then imaged by fluorescence- 
scanning confocal microscopy. The results indicate that 
TRAIL induces blebbing of the cellular membrane and re- 
lease of apoptotic vesicles that is indistinguishable from 
the effect of cross-linking antibody to Fas (Figure 56, pan- 
els A-C). Green fluorescence of cellular cytoplasm is due 
to activation of calcein AM by a cytoplasmic esterase. Also 
similar to the effect of antibody to Fas, TRAIL induces the 
rapid destruction of the cytoskeleton and breakdown of 
nuclear integrity (Figure 58, panels D-F). In these panels, 
F-actin appears green due to staining with a BODIPY FL- 
conjugated phallacidin, and nuclei appear red due to stain- 
ing with propidium iodide. These changes in cellular mor- 
phology are indicative of apoptosis (Wyllie et al., 1992). 
Since TRAIL was found to induce apoptosis in Jurkat 
and U937 cells, the effect of TRAIL on various other cell 
lines was also tested. Cell lines indicated in Table 1 were 
assayed by incubation for 20 hr with conditioned superna- 
tants from pDC409-Flag-TRAIL transfected CVllEBNA 
cells versus supernatants from cells transfected with 
empty vector, in the presence of immobilized anti-flag anti- 
body. Metabolic activity was assayed by conversion of ala- 
mar blue dye. As shown in Table 1, many cell lines of 
hematopoietic origin are sensitive to TRAIL-mediated kill- 
ing. True cell death (apoptotic in nature) was confirmed 
by trypan blue staining and visualization of apoptotic frag- 
mentation by microscopy (data not shown). In addition, 
some cell lines were not killed by TRAIL, indicating that 
TRAIL-induced apoptosis is target cell specific. 
Interspecies cross-reactivity of human and murine 
TRAIL was tested by incubating murine TRAIL with the 
human melanoma line A375Since this is an adherent cell 
line, the crystal violet assay, rather than alamar blue, was 
used to determine viability. The results demonstrate that 
both human and murine TRAIL are active on these human 
cells (Figure 8A). Conversely, to test the ability of human 
TRAIL to act on murine cells, we utilized the murine fibro- 
blast cell line L929. As shown in Figure 8B, incubation of 
L929 cells with either human or murine TRAIL results in 
a decrease in crystal violet staining, thus demonstrating 
that human TRAIL is also activeon murine cells. In addition 
to crystal violet, cell death was confirmed by trypan blue 
staining (data not shown). 
Chromosomal Mapping of TRAIL 
To determine where the TRAIL gene resides in the human 
genome, metaphase chromosomes from two normal 
males were analyzed by fluorescent in situ hybridization. 
From one male, 20 metaphases were examined for fluo- 
rescent signal. All of these metaphases showed signal on 
one or both chromatids of chromosome 3 in the region 
3q25-q28.3; 64% of this signal was located at bands 
3q28.1 and 3q28.2 (data not shown). There was a total 
of 10 nonspecific background dots observed in these 20 
metaphases. A similar result was obtained from hybridiza- 
tion of the probe to 18 metaphases from a second normal 
male (data not shown). This indicates that the TRAIL gene 
is located in band 3q26 most likely in the region q26.1- 
q26.2. 
In this paper, we have described the molecular cloning 
and biological characterization of a novel member of the 
TNF ligand family. Like all but one other member of this 
family, the predicted TRAIL protein product has the char- 
acteristics of a type II membrane protein, i.e., no leader 
sequence, and an internal transmembrane domain. Also 
like other TNF family ligands, TRAIL has an N-terminal 
(cytoplasmic) domain, which is not conserved across fam- 
ily members, while the C-terminal (extracellular) domains 
show significant conservation (Smith et al., 1994). The 
percent identity of the human extracellular C-terminal do- 
main of TRAIL to the most closely related members of the 
TNF ligand family, Fas ligand, TNFa, LTa, and LT8, is 
28%, 23%, 23%, and 22%, respectively. Alignment of the 
C-terminal amino acid sequences of these related family 
members with human and murine TRAIL is shown in Fig- 
ure 7. The crystal structures of TNF and LTa are known 
and these ligands have been shown to fold into p-pleated 
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Figure 5. Death of Jurkat Cells Induced by Soluble TRAIL 
Jurkat ceils were cultured for 20 hr in the presence or absence of TRAIL under the indicated conditions. Metabolic activity was assayed by 
conversion of alamar blue dye and plotted as a percentage relative to control cultures (A). Shown are confocal microscopic images of Jurkat cells 
in the early stages of apoptosis (B). Cells were treated with medium only (A and D). 20 rig/ml purified TRAIL in the presence of immobilized M2 
antibody to Flag (B and E), or cross-linking antibody to Fas receptor (C and F) for 2.5 hr. The live/dead cell assay used in (A-C) employs a dye 
(calcein AM) that fluoresces green in response to intracellular esterase activity, revealing blebbing of the cellular membrane and release of apoptotic 
vesicles. Ceils in (D-F) are stained with BODIPY FL phallacidin (green), showing a pronounced disruption of the cytoskeleton. The nuclei are 
stained with propidium iodide (red). The solid white bar in (F) indicates a length of 10 uM. 
sheet sandwich structures and to form homotrimers 
(Jones et al., 1989; Eck et al., 1992). The sequences in 
this region that are most conserved map to the strands 
that form these P-pleated sheets, with the centrally located 
D strand having the greatest conservation. Therefore, it 
is likely that TRAIL, like TNF, forms an oligomeric structure 
that is necessary to cross-link its cognate receptor, thereby 
transducing a signal to the target cell. 
In contrast with the extracellular region, the N-terminal 
cytoplasmic domains of previously identified TNF ligand 
family members are conserved across species, though 
not between family members. This fact, combined with 
data demonstrating that cross-linking of some of these 
molecules can directly induce biological effects, suggests 
that some of these ligands may themselves transmit sig- 
nals across the cell membrane (Cayabyab et al., 1994; 
Pollok et al., 1994; Stiiber et al., 1995). However, the short 
cytoplasmic domain of TRAIL is not conserved between 
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Table 1. Effect of Soluble TRAIL on Cell Line Viability 
Cell Line Description Percent Viabilitp 
Bjab Surkitt lymphoma 0.5 f 3.0 
Ramos Burkitt lymphoma 12.1 * 2.1 
u937 Histiocytic lymphoma 25.2 f 8.2 
HL60 Promyelocytic leukemia 59.5 f 3.2 
Raji Burkitt lymphoma 64.9 f 4.5 
Daudi Burkitt lymphoma 70.2 f 4.2 
THP-1 Monocytic cell line 92.3 f 6.8 
K562 Chronic myelogenous leukemia 97.1 * 4.8 
K299 Large cell anaplastic lymphoma 99.0 f 4.3 
MP-1 Spontaneous B cell line 104.9 f 11.7 
“Results are means f SEMs of four wells for each data point. 
species, suggesting that it is unlikely that this domain of 
TRAIL serves a biological function. 
Known biological activity of TRAIL is thus far limited to 
inducing apoptosis in various cell lines, including but not 
restricted to those of hematopoietic origin. Apoptosis, the 
process of programmed cell death, is necessary for the 
normal development and homeostasis of an organism, 
and involves dramatic changes in cellular structure. TRAIL 
has been shown in this paper to induce many of these 
changes such as blebbing of the cellular membrane, dis- 
ruption of the cytoskeleton, fragmentation of DNA into 
- 180 bp multimers, and decimation of metabolic activity 
(Figures 3, 5). While some members of the ligand family, 
such as TNF and LTa, can induce apoptosis in certain 
cell lines, of the known family members, only Fas ligand 
and TRAIL have the ability to kill such a wide variety of 
cell lines. Intriguingly, of the known TNF ligand family 
members, the primary sequence of TRAIL is most closely 
related to Fas ligand. 
The in vivo role of Fas or Fas ligand in apoptosis has 
been shown by spontaneous mutations in mice (Wata- 
nabe-Fukunagaet al., 1992; Lynchet al., 1994;Takahashi 
et al., 1994) and in humans (Fisher et al., 1995; Rieux- 
Laucat et al., 1995), which result in lymphadenopathy and 
development auto-immune disease. Unfortunately, insight 
into the in vivo role of TRAIL is not offered by its location 
on chromosome 3, since, at this time, no human disease 
with asimilar phenotype has a locus that has been mapped 
nearby. Of course, this does not eliminate the potential 
role of TRAIL in disease, since many human diseases 
have not yet been mapped. Also, it has previously been 
observed that some of the TNF-related genes are clus- 
tered in the genome. TNF, LTa, and LTj3 are tightly linked 
on chromosome 8, while CD27 ligand and 4-1BB ligand 
both map to chromosome 19p13.3 (Browning et al., 1993; 
Goodwin et al., 1993b). In contrast, TRAIL does not map 
near any of the known TNF ligand family members. This 
does not preclude, of course, clustering with other TNF 
family members that are as yet unidentified. 
One significant difference between TRAIL and Fas li- 
gand is the tissue distribution of their transcripts. Unlike 
Fas ligand, whose transcripts appear to be largely re- 
stricted to stimulated T cells (Suda et al., 1993,1995) (Fig- 
ure 2) significant levels of TRAIL are seen in many tissues, 
and it is constitutively transcribed by some cell lines. 
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Figure 6. Cross-Species Activity of Human and Murine TRAIL 
Cells were incubated with various factors as indicated and viability 
wasassayed bystainingwith crystalvioletdyeandplottedasapercent- 
age of control cultures. Starting concentrations of factors are shown 
in the legend, and the horizontal axis indicates the number of serial 
P-fold dilutions of those factors. The effect of human and murine solu- 
ble TRAIL on human A375 cell viability is plotted (A). The effect of 
human and murine soluble TRAIL on murine L929 cell viability is plot- 
ted (6). 
Therefore, TRAIL must not be cytotoxic to most tissues 
in vivo. However, it is interesting to note that TRAIL tran- 
scripts are not found in the liver, the same organ that is 
destroyed by in vivo injection of antibody to the Fas recep 
tor (Watanabe-Fukunaga et al., 1992). TRAIL transcripts 
are present in the thymus, whereas Fas ligand is not (Suda 
et al., 1995) (Figure 2). Furthermore, unlike Fas ligand, 
TRAIL, acting as a single agent, does not kill freshly iso 
lated murine thymocytes (Ogasawara et al., 1995; H. J. 
McKenna, unpubl,ished data). This does not rule out a role 
for TRAIL in deletion of inappropriate Tcells in the thymus, 
but if TRAIL is involved in thymic selection, additional sig- 
nals are required to induce apoptosis. Also, TRAIL acting 
as a single agent does not induce apoptosis in primary B 
cells or T cells (data not shown), and TRAIL has not been 
able to costimulate primary T cells to proliferate in the 
presence of suboptimal amounts of anti-CD3 (data not 
shown). 
Given the rather widespread expression of TRAIL and 
its ability to induce apoptosis in so many different types 
of cultured cells, it is reasonable to infer that either the 
TRAIL receptor is restricted in its distribution, or that it 
acts to induce apoptosis only under certain restricted cir- 
cumstances. Interaction of known TNF receptor family 
members and TRAIL was tested using a very sensitive 
radio-binding assay. Labeled fusion proteins of the extra- 
cellular domains of TNF receptor family members and im- 
munoglobulin Fc were used to probe CVl/EBNA cells 
transfected with either pDC409-TRAIL or a similar vector 
expressing the known cognate ligand. While strong sig- 
nals were seen in the cells expressing the known ligands, 
no signal above background was seen with the TRAIL- 
expressing cells, indicating that no known member of the 
TNF receptor family binds to TRAIL (data not shown). 
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Figure 7. TRAIL Sequence Homologies 
Human and murine TRAIL predicted amino acid sequences were aligned with other TNF ligand family members. The entire predicted amino acid 
sequence of the human and murine TRAIL genes are aligned, and alignments of other ligands start where significant homology begins. Solid 
background shows identity with at least one aligned residue in another family member, or between the murine and human sequences. Solid bars 
marked with letters B-l indicate 6 strands in the TNFa crystal structure. The shaded bar marked TM indicates the transmembrane region. The 
arrow indicates the N terminus of the coding regions used to make soluble versions of the human and murine ligands. 
These data are corroborated by the failure of blocking 
antibody to Fas receptor to prevent TRAIL-induced 
apoptosis (Figures 4 and 5) and the ability of Fas ligand 
to induce apoptosis in primary thymocytes whereas TRAIL 
does not (Ogasawara et al., 1995; H. J. McKenna, unpub- 
lished data). Therefore, it is likely that the receptor for 
TRAIL is a novel member of the TNF receptor family, 
which, when identified, should provide valuable insight 
into the biological function of TRAIL. 
Experimental Procedures 
CalIS 
The MP-1 line is a spontaneously derived Epstein-Barr virus-trans- 
formed B cell line (Goodwin et al., 1993a). K299 (DSMACC31) was 
established from peripheral blood of a male diagnosed with high grade 
LCAL (Fischer et al., 1966). Other cell lines referred to in this paper 
have been deposited in and described by the American Type Culture 
Collection (Rockville, Maryland). A375 cells were cultured in DMEM 
medium supplemented with 10% fetal bovine serum, 100 ug/ml strep- 
tomycin, and 100 pa/ml penicillin. All other cell lines were cultured to 
a density of 200,000-500,000 cells per ml in RPM1 medium supple- 
mented with 10% fetal bovine serum, 100 ug/ml streptomycin, and 
106 pg/ml penicillin. 
Cloning of the TRAIL cDNA 
An EST that potentially encodes a novel TNF ligand family member 
was identified in the dbEST data base at the National Center for Bio- 
technology Information by performing a TBLASTN search using the 
query sequence LWXXXGLYYVYXQVXF (GenBank accession num- 
ber 236726). This sequence is based upon the most conserved region 
of the TNF ligand family, the D strand. This EST sequence was ob 
tained from a heart atrium cDNA library submitted by Genzentrum 
Muenchen, Laboratorium fiir molekulare Biologie (Klopferspitz lSa, 
62152 Martinsried, Federal Republic of Germany). 
Oligonucleotides (30 bp) were synthesized based upon the se- 
quences from the 5’ and 3’ ends of this EST file: TGACGAAGAGAG- 
TATGAACAGCCCCTGCTG and TGAAATCGAAAGTATGTTTGGGA- 
ATAGATG, respectively. Of each oligonucleotide, 50 ng were labeled 
with [PPJTATP and polynucleotide kinase. lgtl0 cDNA libraries (2) 
were screened by conventional methods (Sambrook et al., 1969) using 
an equimolar mixture of these labeled oligonucleotides as probe. One 
library was a human heart 5’ stretch cDNA library (Stratagene), and 
the otherwasa human PBLlibrarythat has been previously described: 
(Idzerda et al., 1990). Nitrocellulose filters were lifted from these plates 
in duplicate, and hybridized overnight with the kinased oligonucleo- 
tides at 67OC in a solution of 60 mM Tris (pH 6.0) 2 mM EDTA, 5 x 
Denhardt’s solution, 6x SSC, 1 mg/ml n-lauroyl sarcosine, 0.5% 
NP40, and 4 pg/ml denatured salmon sperm DNA. The filters were 
then washed in 3 x SSC at 67°C for 30 min. One positive plaque was 
obtained from approximately 1Q plaques using a heart C’stretch cDNA 
library (Stratagene). Approximately 50 positive plaques were obtained 
out of 5 x 1oJ plaques using the PBL library. Of these first round 
positive plaques, 15 were picked and the inserts from the enriched 
pools were amplified using oligonucleotide primers designed to amplify 
phage inserts. The resulting products were resolved by 1.5% agarose 
gel electrophoresis, blotted onto nitrocellulose, and analyzed by stan- 
dard Southern blot technique using the two kinased EST oligonucleo- 
tides as probes. The two plaque picks that produced the largest bands 
by the Southern blot analysis were used for secondary screening, and 
isolated phage plaques were obtained using the same procedures as 
described above. DNA from the isolated phage were prepared by the 
plate lysis method, and the cDNA inserts were excised with EcoRI, 
and ligated into the pBluescript SK(+) plasmid (Stratagene). These 
inserts were then sequenced by conventional methods, and the re- 
sulting sequences were aligned. 
A previously described cDNA library (Mosley et al., 1969) prepared 
from the murine helper T cell line 789 in li Zap vector (Stratagene) 
was screened with a random primed probe of a 643 bp polymerase 
chain reaction (PCR) product of the human TRAILcDNA, which encom- 
passed the TRAIL coding region. Nitrocellulose filter lifts were hybrid- 
ized as previously described (Mosley et al., 1969) except that the 
temperature was lowered to 37°C. The filter lifts were then washed 
at 50°C in 1 x SSC, 0.1% SDS. Positive clones were purified and the 
inserts excised as pBluescript clones using helper phage as described 
by the manufacturer. 
DNA8 
Oligonucleotides were synthesized corresponding to the B’and 3’ends 
of the coding regions of the human TRAIL gene with Sal1 and Not1 
restriction sites appended to the ends of the oligonucleotides. The 
sequence of the 5’and 3’oligonucleotides respectively, are as follows: 
GCACGTCGACCAGGATCATGGCTATGATGG and CGTGAGCGGC- 
CGCCAGGTCAGT-TAGCCAACT. 
The coding region of the human TRAIL gene was amplified by stan- 
dard PCR techniques, cut with Sal1 and Notl, and inserted into the 
Sal1 and Not1 sites of the pDC409 mammalian expression vector (Smith 
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et al., 1993) or the pBluescript SK(+) (Stratagene) vector to create 
pDC409-TRAIL and pBluescript-TRAIL, respectively. 
pDC409-Flag-TRAIL was created by PCR amplification of TRAIL 
cDNA encoding amino acids 95-261. The 3’ oligonucleotide was the 
same as used to create pDC409-TRAIL and the 5’oligonucleotide was 
GTCACTAGT-TCTGACTACAAGGACGACGATGACAAGACCTCTGA- 
GGAAACCATTTC, which adds a Spel site and synthetic Flag epitope 
encoding region to the 5’ end (Hopp et al., 1966). The resulting PCR 
product was cut with Spel and Notl, and inserted into Sal1 and Not1 
cut pDC409 along with annealed oligonucleotides encoding a putative 
CMV open reading frame leader (Rawlinson and Barrell, 1993). This 
produced an open reading frame encoding the CMV leader, the Flag 
epitope, and human TRAIL amino acids 95-261. A parallel construct, 
pDC409-Flag-muTRAIL, was created in the same way but using a 
PCR fragment generated from the murine TRAIL cDNA using the 5’ 
and 3’ PCR primers GCGTCACTAGTTCTGACTACAAGGACGAC- 
GATGACAAGACCTFPCAGGACACCATFTC and ATAGCGGCCGCT- 
GTGllTGATClTTACTGGTC, respectively. 
Purlflcstlon of Soluble TRAIL 
Supernatants from CVIIEBNA cells were harvested 3 days after trans- 
fection with pDC409-Flag-TRAIL. These were applied to a column 
containing the M2 anti-Flag antibody (Hopp et al., 1966) immobilized 
to a solid support, and washed with PBS. Fractions (600 ml) were 
eluted with 50 mM citrate and immediately neutralized in 0.45 ml 1 M 
Tris (pH 6). Fractions were adjusted to 10% glycerol and stored at 
-20°C until needed. 
RNA Hybrldfzstlon 
Northern blot analysis of RNA samples was performed by using 
Clonetech (Palo Alto, California) multiple tissue Northern blots I and 
II, or by resolving RNA samples on a 1 .I% agarose-formaldehyde 
gel and blotting onto Hybond-N as recommended by the manufacturer 
(Amersham Corporation), and staining with methylene blue to monitor 
RNA concentrations. Antisense RNA probe was generated using T3 
RNA polymerase and pBluescript-TRAIL linearized with Sal1 as tem- 
plate. 
DNA Laddering Apoptosls Assay 
CVllEBNA cells grown in Falcon T175 flasks were transfected with 
15 ug of either pDC409 or pDC409-TRAIL vector. These cells were 
then cultured for 3 days at 37OC and 10% CO?, then fixed as previously 
described (Smith et al., 1993). Of these cells, 4 x IO per well were 
cocultured in a 6-well plate with 2.5 ml of medium with the indicated 
combinations of fixed cells or concentrated supernatants from COS 
cells transfected with Fas ligand. Indicated cells were pretreated for 
IO min with IO pglml of M3, a monoclonal antibody to Fas receptor 
(Ramsdell et al., 1994; Alderson et al., 1995). After incubation for 4 
hr at 37OC and 10% CO?, fragmented DNA in the cytoplasm was 
recovered as described (Ishida et al., 1992) except the cell lysates 
were extracted three times with 1 ml of 25:24:1 phenol-chloroform- 
isoamyl alcohol, and ethanol precipitated in the presence of 5 pg of 
glycogen carrier. 
Percent Vlsbillty Assay 
Cells were incubated with the indicated factors in 96well plates in a 
volume of 100 pl. and assayed by alamar blue (Figure 5A; Table 1) 
or crystal violet (Figure 6). All cells were cultured at 5 x IO6 cells per 
well except for A375 cells, which were cultured at 1 x IO’ cells per 
well. Where indicated, immobilized anti-Flag antibody, M2, was added 
at a concentration of 10 ttg/ml in a volume of 100 ul per well (Hopp 
et al., 1968) and allowed to adhere either overnight at 4OC or 2 hr at 
37OC, then aspirated and washed twice with PBS. The incubation 
period was 20 hr for all cells, except the A375 cells, which were incu- 
bated for 72 hr. Conditioned supernatants were used at a concentration 
of 10 ul per well. Alamar blue conversion was measured by adding 
10 nl of alamar bluedye (Biosource International, Camarillo, California) 
per well, and subtracting the OD at 550-600 nm at the time the dye 
was added from the OD 550600 nm after 4 hr. No conversion of dye 
is plotted as 0% viability, and the level of dye conversion in the absence 
of TRAIL is plotted as 100% viability. When shown, error bars repre- 
sent the standard deviation of measurements from four independent 
wells, and the values are the average of these measurements. Crystal 
violet staining was performed as described (Flick and Gifford, 1964). 
Percent viability is calculated by multiplying the ratio staining of experi- 
mental versus control cultures by 100. To confirm that the changes 
in dye activities of both the alamar blue and crystal violet assay were 
due to cell death, the decrease in cell viability induced by TRAIL was 
confirmed by staining the cells with trypan blue. 
Confocal Mlcroscopy 
Live/dead viability/cytotoxicity assays were performed as recom- 
mended by the manufacturer (Molecular Probes, Incorporated, Eu- 
gene, Oregon). BODIPY FL phallacidin and propidium iodide were 
purchased from Molecular Probes. Cells were stained with these re- 
agents and visualized using a confocal laser scanning microscope as 
recommended by the microscope manufacturer (Molecular Dynamics, 
Sunnyvale, California). 
Chromosomal Mapplng 
The human TRAIL coding region was nick-translated with biotin-14 
dATP and hybridized in situ at a final concentration of 20 rig/ml to 
metaphases from normal males. The fluorescence in situ hybridization 
method was modified from that previously described (Callen et al., 
1990) in that chromosomes were stained before analysis with both 
propidium iodide (as counterstain) and DAPI (for chromosome identifi- 
cation). Images of metaphase preparations were captured by CCD 
camera and computer enhanced. 
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